Skip to content

NIPT Education for Labs

Considerations for Your Lab

Until 2011, the predominant prenatal aneuploidy screening options for trisomies 21, 18, and 13 were measurement of serum markers and sonographic evaluation of the fetus. The introduction of cell-free DNA (cfDNA) screening created a new option—noninvasive prenatal testing (NIPT)—that facilitates screening for a wider range of fetal aneuploidies. Like traditional serum screening, NIPT is a screening test and results should be confirmed by diagnostic testing prior to making pregnancy management decisions.

We have compiled the following information to consider as your lab evaluates which prenatal tests to offer, and what technology to select to carry you into the future and provide your lab with the best return on investment.

  • What is cell-free DNA (cfDNA) and why is it beneficial?
  • How to evaluate NIPT vs other screening methods

Technologies Used for NIPT

Cell-Free DNA Technology for NIPT

Understand what cfDNA is and how it is used to provide a more accurate screening test for the detection of fetal aneuploidy.

Learn More
NIPT vs. Conventional Aneuploidy Screening Methods

NIPT has consistently demonstrated increased detection (higher sensitivity) and higher specificity (less false positive cases) for aneuploidy than traditional screening.

Learn More
Illumina and Harvard Pilgrim Partner on Value-Based Contract

Illumina and Harvard Pilgrim Partner on Value-Based Contract

Announce first ever next-generation sequencing agreement for non-invasive prenatal testing.

Read Article

A Guide to NIPT Technology Options

Learn more about evaluating NIPT options and key considerations when selecting a technology for your lab.

Download Guide

Additional Resources

Implications of Test Failures: A Webinar with Professor Yuval Yaron
Implications of Test Failures: A Webinar with Professor Yuval Yaron

Professor Yuval Yaron discusses the implications of test failures.

View Webinar
NIPT: Effective Screening for the General Pregnancy Population

Glenn Palomaki, PhD, discusses the clinical validity and utility of offering noninvasive prenatal testing (NIPT), also known as cell-free DNA screening, as a primary screen in the general pregnancy population.

View Webinar
Clinical Experience Supporting the Verifi Prenatal Test

This webinar helps you become more familiar with clinical experience studies that support the Verifi Prenatal test offerings.